T Cell–Activating Bispecific Antibodies in Cancer Therapy
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Effector lymphocytes are multifunctional cells of the immune system that promote cytolysis of pathogen-infected cells and nascent tumors. Tumors must learn to evade effectors and employ a wide variety of mechanisms to do so. Bispecific Abs (BsAbs) are an emerging cancer immunotherapy approach seeking to re-engage either T effectors or NK cells with malignant cells. Possessing specificity for effector cells on one end and a tumor Ag on the other, these molecules work by attracting effectors to the target cell to build an immunologic synapse and induce tumor cell killing. The BsAb blinatumomab, for example, has specificity for the T cell–activating cell surface protein CD3 and the B cell Ag CD19. The only BsAb with regulatory approval currently, blinatumomab is used in the treatment of relapsed or refractory B cell acute lymphoblastic leukemia. Many additional BsAbs are in preclinical development, however, targeting many different tumor types. The variety of potential effector cells and cancer Ags, along with potential combination therapies, make BsAbs an active area of drug development. In this review, we discuss cancer recognition by the immune system and structural and mechanistic aspects of BsAbs. We summarize key steps in preclinical development and subsequent translation to medical practice. Future directions for BsAbs include combinations with a wide variety of both immunologic and nonimmunologic therapies. Defining their optimum clinical use is at early stages.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709684 · Cited by 5,357 · cited 1×
“Successful development efforts include immune checkpoint inhibitors to counteract tumors’ immune-inhibitory signals (3, 4), reprogramming of T cells to attack tumors with chimeric Ag receptors (CARs) (5, 6), and, finally, bispecific Abs”
BackgroundBrentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005930 · Cited by 2,063 · cited 1×
“Successful development efforts include immune checkpoint inhibitors to counteract tumors’ immune-inhibitory signals (3, 4), reprogramming of T cells to attack tumors with chimeric Ag receptors (CARs) (5, 6), and, finally, bispecific Abs”
BackgroundTopp, M. S., Gökbuget, N., Stein, A. S., Zugmaier, G., O'Brien, S., Bargou, R. C., Dombret, H., Fielding, A. K., Heffner, L., Larson, R. A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71170-2 · Cited by 1,269 · cited 20×
“It does not seem to be related to CNS involvement by disease, as those patients typically were excluded from clinical trials (54).”
BackgroundInfluentialAlternative molecular formats and therapeutic applications for bispecific antibodies
Spiess, C., Zhai, Q., & Carter, P. J. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.01.003 · Cited by 607 · cited 1×
“It is a full-length IgG1 BsAb with near-native architecture using “knobs-into-holes” technology (14, 33).”
MethodBispecific T-Cell Engaging Antibodies for Cancer Therapy
Baeuerle, P. A., & Reinhardt, C. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0547 · Cited by 592 · cited 1×
“as activating magnets between effector and tumor cells (10, 11).”
BackgroundComprehensive analysis of the clinical immuno-oncology landscape
Tang, J., Shalabi, A., & Hubbard-Lucey, V. M. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx755 · Cited by 508 · cited 1×
“Options now include a diverse selection of small-molecule–targeted inhibitors, mAbs against tumor Ags with and without attached toxic cargoes, and several novel immunotherapies (1, 2).”
BackgroundLöffler, A., Kufer, P., Lutterbüse, R., Zettl, F., Daniel, P. T., Schwenkenbecher, J. M., Riethmüller, G., Dörken, B., & Bargou, R. C. (2000) · Blood · doi:10.1182/blood.v95.6.2098 · Cited by 445 · cited 1×
“Work by German scientists beginning in the mid-90s provided major breakthroughs on the road to blinatumomab, creating the initial fusion between CD3 and CD19 scFvs, establishing production with adequate yield as a single polypeptide, and demonstrating activation of unstimulated T cells against various human B cell lym…”
BackgroundOffner, S., Hofmeister, R., Romaniuk, A., Kufer, P., & Baeuerle, P. A. (2006) · Molecular Immunology · doi:10.1016/j.molimm.2005.03.007 · Cited by 365
Mack, M., Riethmüller, G., & Kufer, P. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.15.7021 · Cited by 351 · cited 1×
“Work by German scientists beginning in the mid-90s provided major breakthroughs on the road to blinatumomab, creating the initial fusion between CD3 and CD19 scFvs, establishing production with adequate yield as a single polypeptide, and demonstrating activation of unstimulated T cells against various human B cell lym…”
BackgroundHoffmann, P., Hofmeister, R., Brischwein, K., Brandl, C., Crommer, S., Bargou, R., Itin, C., Prang, N., & Baeuerle, P. A. (2005) · International Journal of Cancer · doi:10.1002/ijc.20908 · Cited by 344 · cited 2×
“(19) found that CD3/CD19 TAB administration recruited T cells for multiple rounds of target B cell lymphoma tumor elimination.”
Background
Cited by
Breast Cancer Treatments: Updates and New Challenges
Burguin, A., Diorio, C., & Durocher, F. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11080808 · Cited by 488
Kerns, S. J., Belgur, C., Petropolis, D., Kanellias, M., Barrile, R., Sam, J., Weinzierl, T., Fauti, T., Freimoser-Grundschober, A., Eckmann, J., et al. (2021) · eLife · doi:10.7554/elife.67106 · Cited by 82
“Consistent with the expression of EpCAM in the gastrointestinal tract, the molecule triggered severe diarrhea and ultimately prevented escalation to efficacious doses and the identification of a therapeutic window (Kebenko et al., 2018; Trabolsi et al., 2019).”
Dang, K., Castello, G., Clarke, S. C., Li, Y., Balasubramani, A., Boudreau, A., Davison, L., Harris, K. E., Pham, D., Sankaran, P., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002488 · Cited by 76
Sawyer, W. S., Srikumar, N., Carver, J., Chu, P. Y., Shen, A., Xu, A., Williams, A. J., Spiess, C., Wu, C., Liu, Y., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1917383117 · Cited by 55
“The major impact of antibody therapeutics in treating diseases, such as cancer, has led to the rise of many new format large molecules (18), such as bispecific antibodies (19, 20), which enables the binding of multiple antigens that are useful for many therapeutic applications.”
BackgroundSolution structure and synaptic analyses reveal determinants of bispecific T cell engager potency
Leithner, A., Staufer, O., Mitra, T., Liberta, F., Valvo, S., Kutuzov, M., Dada, H., Spaeth, J., Zhou, W., Schiele, F., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2425781122 · Cited by 22
Metadata
- Authors
- Trabolsi, A., Arumov, A., & Schatz, J. H.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-08-01
- Volume
- 203
- Issue
- 3
- Pages
- 585-592
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2963299652
- Cited by
- 70
- References
- 17
- FWCI
- 6.45
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.